A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
Open Access
- 23 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, FHIT is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition.Keywords
This publication has 55 references indexed in Scilit:
- Focal adhesion signaling and therapy resistance in cancerSeminars in Cancer Biology, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011
- OsteosarcomaAnnals of Oncology, 2010
- Fhit regulates invasion of lung tumor cellsOncogene, 2009
- ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid LeukemiaClinical Cancer Research, 2006
- Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomasLiver International, 2005
- Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic MarkersCancer Epidemiology, Biomarkers & Prevention, 2005
- Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor CellsClinical Cancer Research, 2005
- Inactivation of the FHIT Gene Favors Bladder Cancer DevelopmentClinical Cancer Research, 2004
- Abnormalities of theFHITTranscripts in Osteosarcoma and Ewing SarcomaJapanese Journal of Cancer Research, 1998